# Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

> **NCT05258279** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Juntendo University** · enrollment: 30 (estimated)

## Conditions studied

- Non-squamous Non-small-cell Lung Cancer
- EGFR Activating Mutation

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Lenvatinib
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT05258279
- **Lead sponsor:** Juntendo University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-01
- **Primary completion:** 2023-10-31
- **Final completion:** 2024-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05258279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05258279, "Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT05258279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*